Literature DB >> 1752444

DNA-binding properties of the HMG domain of the lymphoid-specific transcriptional regulator LEF-1.

K Giese1, A Amsterdam, R Grosschedl.   

Abstract

Lymphoid enhancer-binding factor 1 (LEF-1) is a pre-B and T lymphocyte-specific nuclear protein that participates in the regulation of the T-cell antigen receptor (TCR) alpha enhancer by binding to the nucleotide sequence 5'-CCTTTGAA. LEF-1 protein shares with the nonhistone high mobility group protein 1 (HMG-1) and several transcriptional regulators a single region of amino acid homology, termed the HMG box, which has been implicated in DNA binding. Here, we report the biochemical analysis of the interaction of this novel structural motif with DNA. First, amino- or carboxy-terminal truncations of the LEF-1 polypeptide delineated the HMG box as the DNA-binding domain. We purified to homogeneity a LEF-HMG domain peptide expressed in Escherichia coli and determined the equilibrium constant for specific binding to DNA as 1 x 10(-9) M. Second, cotranslation of wild-type and various truncated LEF-1 polypeptides did not generate any DNA-binding heterodimers, suggesting that LEF-1 can bind DNA as a monomer. Third, methylation interference analysis indicated that the HMG domain specifically contacts DNA on one side of the double helix. Finally, changes of amino acids that are conserved among various members of the family of HMG-box proteins decreased the affinity of DNA binding by one to three orders of magnitude. Together, these data define the characteristics of specific DNA-binding by the HMG domain of LEF-1.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752444     DOI: 10.1101/gad.5.12b.2567

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  87 in total

1.  DNA looping in the RNA polymerase I enhancesome is the result of non-cooperative in-phase bending by two UBF molecules.

Authors:  V Y Stefanovsky; G Pelletier; D P Bazett-Jones; C Crane-Robinson; T Moss
Journal:  Nucleic Acids Res       Date:  2001-08-01       Impact factor: 16.971

Review 2.  T-cell factors: turn-ons and turn-offs.

Authors:  Adam Hurlstone; Hans Clevers
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

3.  The role of intercalating residues in chromosomal high-mobility-group protein DNA binding, bending and specificity.

Authors:  Janet Klass; Frank V Murphy; Susan Fouts; Melissa Serenil; Anita Changela; Jessica Siple; Mair E A Churchill
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

4.  Role of canonical Wnt signaling/ß-catenin via Dermo1 in cranial dermal cell development.

Authors:  Thu H Tran; Andrew Jarrell; Gabriel E Zentner; Adrienne Welsh; Isaac Brownell; Peter C Scacheri; Radhika Atit
Journal:  Development       Date:  2010-10-27       Impact factor: 6.868

5.  Discovery of inhibitors of aberrant gene transcription from Libraries of DNA binding molecules: inhibition of LEF-1-mediated gene transcription and oncogenic transformation.

Authors:  James S Stover; Jin Shi; Wei Jin; Peter K Vogt; Dale L Boger
Journal:  J Am Chem Soc       Date:  2009-03-11       Impact factor: 15.419

6.  Expression of the lymphoid enhancer factor 1 is required for normal hematopoietic stem and progenitor cell function.

Authors:  K E Edmaier; K Stahnke; N Vegi; M Mulaw; S Ihme; A Scheffold; K L Rudolph; C Buske
Journal:  Leukemia       Date:  2013-08-14       Impact factor: 11.528

7.  Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas.

Authors:  Aatur D Singhi; Mhammed Lilo; Ralph H Hruban; Kristi L Cressman; Kimberly Fuhrer; Raja R Seethala
Journal:  Mod Pathol       Date:  2014-03-21       Impact factor: 7.842

8.  Interaction between a novel F9-specific factor and octamer-binding proteins is required for cell-type-restricted activity of the fibroblast growth factor 4 enhancer.

Authors:  L Dailey; H Yuan; C Basilico
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor).

Authors:  D K Treiber; X Zhai; H M Jantzen; J M Essigmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

10.  Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with beta-catenin.

Authors:  Claudio Sustmann; Henrik Flach; Hanna Ebert; Quinn Eastman; Rudolf Grosschedl
Journal:  Mol Cell Biol       Date:  2008-03-17       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.